The LAST ACT Trial is a parallel-group, randomised (1:1), double-blind, placebo-controlled, multi-centre Phase III non-inferiority trial comparing dexamethasone versus placebo for 6-8 weeks in addition to standard anti-tuberculosis treatment in HIV-uninfected patients with TBM stratified by LTA4H genotype.